May 2011 - GlaxoSmithKline GlaxoSmithKline’s China R&D center has followed a steady but slow growth. In 2007, GSK announced the establishment of a USD 40 million Shanghai R&D center which, among other functions, would serve as the company’s primary center focusing on neurodegenerative disorders.
As of 2008, the company had increased its staff from 170 to 200 and stated its intention to double this number by the end of this year, as well as pursue drug discovery efforts in addition to pre-clinical and clinical trial support.
In December 2007, GSK said it expected to have invested $100 million in its Shanghai facility by the end of 2008 and have 1.000 staff members employed there by 2010.
When it was started, GSK’ Shanghai R&D center had the stated goal of focusing on neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The Shanghai center was tasked with eventually directing GSK’s R&D activities in this therapeutic area, coordinating with other GSK centers around the world and research institutions in China and globally.
The Shanghai center began operations in the summer of 2007.
GSK Shanghai China
Building 3, 898 Halei Rd,
Zhangjiang Hi-Tech Park,
Pudong,
Shanghai, China
